Zoetis (ZTS) Research & Development (2012 - 2026)
Zoetis' (ZTS) quarterly Research & Development came in at $180.0 million in Q1 2026, up 11.11% year-on-year from $162.0 million in Q1 2025, and down 9.55% on a QoQ basis from $199.0 million in Q4 2025.
Zoetis (ZTS) Research & Development (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 13 years of Research & Development data on file, last reported at $180.0 million in Q1 2026.
- On a quarterly basis, Research & Development rose 11.11% year-over-year to $180.0 million in Q1 2026; TTM through Mar 2026 was $721.0 million, a 5.1% increase from a year earlier, with the FY2025 full-year figure at $698.0 million, up 1.75% from the prior year.
- Research & Development for Q1 2026 stood at $180.0 million, down from $199.0 million in the prior quarter.
- Over the last five years, Research & Development for ZTS reached as high as $199.0 million in Q4 2025 and fell as low as $122.0 million in Q1 2022.
- Historically, Research & Development has averaged $160.1 million across 5 years, with a median of $162.0 million in 2024.
- Across the five-year window, Research & Development rose 17.57% in 2023 and changed 0.0% in 2025, its largest moves.
- Year by year, Research & Development stood at $148.0 million in 2022, then gained by 17.57% to $174.0 million in 2023, then grew by 6.9% to $186.0 million in 2024, then climbed by 6.99% to $199.0 million in 2025, then slipped by 9.55% to $180.0 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $180.0 million in Q1 2026, $199.0 million in Q4 2025, and $170.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 180.00 Mn |
| Dec 31, 2025 | 199.00 Mn |
| Sep 30, 2025 | 170.00 Mn |
| Jun 30, 2025 | 172.00 Mn |
| Mar 31, 2025 | 162.00 Mn |
| Dec 31, 2024 | 186.00 Mn |
| Sep 30, 2024 | 167.00 Mn |
| Jun 30, 2024 | 171.00 Mn |
| Mar 31, 2024 | 162.00 Mn |
| Dec 31, 2023 | 174.00 Mn |
| Sep 30, 2023 | 152.00 Mn |
| Jun 30, 2023 | 146.00 Mn |
| Mar 31, 2023 | 142.00 Mn |
| Dec 31, 2022 | 148.00 Mn |
| Sep 30, 2022 | 134.00 Mn |
| Jun 30, 2022 | 135.00 Mn |
| Mar 31, 2022 | 122.00 Mn |
| Dec 31, 2021 | 138.00 Mn |
| Sep 30, 2021 | 132.00 Mn |
| Jun 30, 2021 | 120.00 Mn |